Iohexol

Summary

Iohexol (CHEMBL1200455) is an approved small-molecule radioopaque medium (ATC V08AB02); indicated across 9 conditions including myocardial ischemia and acute kidney injury.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08AB02
• Indications: 9 conditions
• Clinical trials: 62
• Chemistry: 821.1 Da · C19H26I3N3O9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200455
Name	Iohexol
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3730
ChEBI	CHEBI:31709
ATC	V08AB02
Molecular formula	C19H26I3N3O9
Molecular weight	821.1
InChIKey	NTHXOOBQLCIOLC-UHFFFAOYSA-N

SMILES: CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I

IUPAC name: 5-[acetyl(2,3-dihydroxypropyl)amino]-1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide

ChEBI definition: A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.

Pharmacological roles (ChEBI): radioopaque medium.

Other ChEBI roles (chemical / environmental): environmental contaminant, xenobiotic.

Also known as: Exypaque, Iohexol, Iohexolum, NSC-759636, Omnipaque, Omnipaque 12, Omnipaque 140, Omnipaque 180, Omnipaque 210, Omnipaque 240, Omnipaque 300, Omnipaque 350

Patent coverage: 3,826 distinct patent families (11,605 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
myocardial ischemia	3	MONDO:0024644	EFO:1001375
acute kidney injury	2	MONDO:0002492	HP:0001919
kidney disorder	2	MONDO:0005240	EFO:0003086
HIV infectious disease	1	MONDO:0005109	EFO:0000764
kidney failure	1	MONDO:0001106	HP:0000083
breast neoplasm	1	MONDO:0021100	MONDO:0007254
neoplasm	1	MONDO:0005070	EFO:0000616
Fabry disease	1	MONDO:0010526	MONDO:0010526

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 62.

Phase distribution

Phase	Trials
Not specified	22
PHASE1	17
PHASE4	11
PHASE3	4
PHASE2	4
EARLY_PHASE1	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05967117	PHASE4	RECRUITING	Chest CT Using Low-concentration Iodine Contrast Media
NCT06709521	PHASE4	RECRUITING	Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)
NCT00478556	PHASE4	COMPLETED	Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT
NCT02246998	PHASE4	COMPLETED	Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults
NCT02522338	PHASE4	COMPLETED	Measurement of Glomerular Filtration Rate (GFR) in HIV Patients: Single-center Study Comparing the Accuracy of Estimators of GFR Versus Iohexol Plasma Clearance
NCT03415997	PHASE4	COMPLETED	Dosing Iodinated Contrast Media According to Lean vs. Total Body Weight
NCT03631771	PHASE4	WITHDRAWN	Pediatric Risk of Hypothyroidism With Iodinated Contrast Media
NCT04113109	PHASE4	COMPLETED	Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2
NCT04649229	PHASE4	COMPLETED	Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3
NCT04742816	PHASE4	COMPLETED	Renal Effects of Hormones/Biomarkers in Transgender PrEP Recipients
NCT05065073	PHASE4	UNKNOWN	Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
NCT01984411	PHASE3	COMPLETED	Comparison of Vascular Access for Radial and Femoral Completion of Diagnostic Cardiac Catheterization
NCT02050269	PHASE3	COMPLETED	Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study
NCT02961478	PHASE3	UNKNOWN	Measurement of Iohexol Plasma Clearance in Patients Leaving ICU After Acute Renal Failure
NCT03689946	PHASE3	COMPLETED	Effect of Evolocumab on Coronary Atherosclerosis
NCT02772276	PHASE2	COMPLETED	Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types
NCT04627831	PHASE2	WITHDRAWN	Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography
NCT05672134	PHASE2	COMPLETED	Evaluation of GeranylGeranylAcetone in Heart Failure With Preserved Ejection Fraction
NCT06820320	PHASE2	COMPLETED	Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy
NCT03997370	PHASE1	ACTIVE_NOT_RECRUITING	Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
NCT05065372	PHASE1	RECRUITING	MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
NCT01214993	PHASE1	COMPLETED	A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects
NCT01839526	PHASE1	TERMINATED	A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
NCT02098174	PHASE1	COMPLETED	Pharmacokinetics of MP-3180 in Healthy Volunteers
NCT02098187	PHASE1	COMPLETED	Pharmacokinetics of MP-3180 and Use of Noninvasive Fluorescence Detection Device in Healthy Volunteers
NCT02342925	PHASE1	COMPLETED	A Study of the Effect of RG1662 on Metformin in Healthy Volunteers
NCT02884089	PHASE1	COMPLETED	A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants
NCT03545087	PHASE1	WITHDRAWN	A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants
NCT03826602	PHASE1	COMPLETED	A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin
NCT04008992	PHASE1	COMPLETED	An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants
NCT04156750	PHASE1	COMPLETED	A Study of LY3556050 in Healthy Participants
NCT04504331	PHASE1	TERMINATED	Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
NCT05105009	PHASE1	COMPLETED	Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function
NCT05136963	PHASE1	UNKNOWN	Development of a Bayesian Estimator for Calculating Plasma Iohexol Clearance
NCT05580250	PHASE1	WITHDRAWN	A Study of LY3526318 in Healthy Male Japanese Participants
NCT05615467	PHASE1	COMPLETED	A Study of Effect of LY3556050 on Metformin in Healthy Participants
NCT04126824	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	Effect of Addition of Steroids on Duration of Analgesia
NCT05754749	EARLY_PHASE1	RECRUITING	Comparison of CE-DBT and MRI in Patients With Known Breast Lesions
NCT06220214	EARLY_PHASE1	RECRUITING	Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
NCT04199754	EARLY_PHASE1	TERMINATED	IV Contrast-Enhanced Cone Beam Computed Tomography (CBCT) in Radiotherapy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).